Member Info for pomander

Malachi's being a naughty little ramper again - he has no idea how many times the Mousetrap has been started and shut down and similarly no idea about the number of expected start and shut downs during the Moustraps useful life. Its all just self serving wishful thinking. There would also seem to me to big a world of difference between a Mousetrap operating continuously over a period of six months across a variety of feedstocks and being tested with plastics and tyre crumb for a few hours at a time. As for claims, based upon intimate personal interactions with KA that the Moustrap is robust and relatively cheap to run and service, I would take them with a very large pinch of salt or better still a large supersonic. Would also be inetresting to know relative to what is teh Moustrap cheap to run and service ? Too many people here just making stuff up.

That's tight Bunion, but only if you hit the more releases tab to bring everything up.. My point is why isn't it under NewsRoom Heading in the first box. ? I think should be plastered over the homepage together with triggered milestone datails.

Obviously all very busy at at RP too, where no time to even update the Newsroom Tab on the website home page since March 2017!

Personally I think RP got the whole thing strategically wrong when they moved into Pharma upon the aquisition of Ple, but sadly too late to reverse that now. They should have ceased all references to multiples earned from legacy mining assets and returns dating back many years to shareholders and again from mining investments. The focus should have been firmly on the potential for Fortacin and how they would select further pharma investments going forwards to benefit HK investors that currently suffer from a lack of pharma companises to invest into on the HKEX. Right now the EU launch is not even plastered all over the website home page. Everything is of course a little contrived in that further pharma investments (outside of the dibbly Dobbly Boot Company which is a story all of its own) have not been considered, nor has any funding or indication of how that funding would be obtained to widen the scope of RP's portfolio to truly become a pharma investment company. All eggs are in one basket here, albeit a treament for Viagra non responders is an exciting prospect if it has legs.

Bignose - doubt we will see a dividend just yet. Dr Mike mentioned a figure of �6 m to complete FDA and the cannister issues would have cost, but you never know.

Version 3, provided by Dr Mike at the 2017 MasterInvestor Show, was that the 87% that responded were offered a free supply of Fortacin for 9 months and zero % declined that offer. No mention of further payment was made, although I not too exercised by that. The trial data and anecdotal stuff, including posts on here, which some may prefer to ignore all seems very postive with regards to efficacy, and not a single horror story which I suspect could cause serious commercial damage.

Promescent is not available in Europe, it has not been approved by the EMA. Despite claims on dodgy websites it is similarly not FDA approved for use in the US, but can be sold as OTC product. It is a hugely inferior product to Fortacin and this has been covered many time on here. If you wish to delve deeper there is a ton of info available on the internet.

Conventional thinking would be price moves or lack of, on such low volumes is not a strong signal of anything in the works.

Well done Bignose - that's that cleared up. Now if you could help JG confirm the poistion with the US and China that would most helpful ! Back in 2014 it was reported that there were at least 6 pharma's interested in the US license ?

Surely the reasons for a director to buy are 1) to potentially benefit form any takeover bid for the company 2)to benefit form a re-rating of the stock once a commercially viable process is proven and 3) to enjoy an endless flow of dividends as has been suggeted here. Selling into 1) & 2) or enjoying 3) is hardly a millstone around your neck. 15k is nothng more than a token buy and I ceratinly would not attach any great significance to it.

I can only see Recordati having direct operations in Tunisia ?

Only a serially abusive Phe shareholder could get excited about combined directors buys of �15k. presumably it confirms no groundbreaking news on the horizon or they would be buying on inside information. Looks tactical to me to get the SP comfortably above 0.50 as surely the AIM ATM is still very much locked and cash reserves must be running down.

Thanks for sharing your vast and impressive knowledge of the PE/ ED market. Interesting how it differs from that of Dr Mike and indeed to a lesser degree Recordati itself. I guess if the past was a perfect guide to the future we would all get it right and all of the time.

Thks - think the focus on the benefits to women is very smart, and nice to see warnings on other snake potions available.

Thanks Alq- your numbers are actually stronger than the ones I initially modelled and performed sensitivity analysis against! That�s a first ! The numbers adopted by RP are derived from their consultants, so if there is any error it lies at the door of their consultants . Your figure of less than 230,000 for Germany is incorrect but not a big deal because as you say there is a large amount of guesswork involved. 230,000 for Germany and 141,000 for Italy alone equates to circa �37m (�99 a pop � I can a year) and I think 8 years to get there is way too conservative. The price point will also inevitably decrease. The real wild card for me is that until now, treatment options have been very limited, SSRI�s have high discontinuation rates and many sufferers will not wish to go down this route. That leaves just a bunch of dodgy sprays with dodgy names that are more a function of marketing campaigns than clinical efficacy. There may be current limitations on internet prescribing but I would expect that to change within your 8 year period � following the lead recently set for Viagra. All in all and in the context of RP�s market cap- prospects look very good as an investment proposition and I still firmly believe RP will be taken out.

Bignose- for the purpose of my own model back in 2014 and based on 2011 population data, I used a combined male population of 154m giving an addressable market of 38 m. It�s probably a little higher now. I then applied a percentage to that addressable mkt for those sufferers that (1) viewed themselves as having a serious condition and (2) those that would actively seek treatment. Lastly I applied a percentage of that market that Fortacin would capture. Best if those wishing to follow this approach apply their own percentage assumptions. In addition to this there is also the recreational/lifestyle market. I note in the corporate presentation that RP apply a percentage of 7.5% of the 25% sufferers in the US. If applied to the E5 market this, would equate to the circa �250 m peak sales mentioned by Dr Mike at last years Master Investor show. I take those figures with a pinch of salt at this stage, mine are much lower. As you correctly say- Recordati has projected (at least in public) sales of between �20 to �25 m for the EU. They have however also guided that these projections may need up lifting due to the inherent difficulties projecting for a new product/mkt. For arguments sake if we take �25 add US (5x) �125m and say �100 m ROW, we get �250 m. Assume average royalty 20% = � 50 m That�s not far off current market cap every year before any other milestones. Add in repeats and life style market and scope for SP growth is massive.

Projections are based upon ''addressable market'' which take into consideration factors that you mention which are widely understood. Don't forget the lifestyle market could be significant. To date only very inferior products available with very high drop out rates for SSRI's which means there is a churn of new sufferers seeking treatment.

Commercial Opportunity The major remaining commercial opportunity in sexual health is for treatment of Viagra/Cialis failures. Almost 50% of ED patients, particularly diabetics, fail to respond adequately to PDE inhibitors. Many of these can be treated by e.g. prostaglandins (Caverject or Edex)but this involves direct injection into the ***** and there is a 30% incidence of pain at the injection site. There is an alternative using a mixture of VIP and phentolamine that is approved in several EU countries but this also involves intra penile injection. There is a high probability that Regent proprietary technology similar to that used in Fortacin will lead to the development of a topical delivery formulation of this agent. The track to market or more realistically outlicensing will be relatively fast as 505(b)(2) and there will be premium pricing as therapy for a special needs population. IP protection will be at least 15 years.

Bignose ''Problem is HK is quite remote and my not be paying attention.'' That's the conundrum - 3 billion shares worth were paying attention immediately post UK launch !

There is no approved treatment other than anti - depressants that work on the CNS and a bunch of dodgy products with dodgy names that most would not expose to their Roger. Depends on your definition of having sex- if your are happy with 30 seconds seems you found the right partner. For fear of sounding like a broken record upteen times over, there has been no marketing effort as yet, UK launch was strategic and not a penny spent on sales and marketing. Marketing is now down to Recordati and other licencees.